Dr. Marco Quarta leads Rubedo Life Sciences, driving its mission to develop treatments for chronic age-related diseases and extend healthspan. Rubedo strategy is based on a platform to discovers the pathological cells involved in the biological aging process, such as senescent-like cells, and to develop small molecules designed for selectively targeting those cells across multiple indications in the Rubedo pipeline.
As a scientist, he earned a Masters degree in Biotechnology, a PhD in Neuroscience, and post-doctoral training in Aging and Stem Cells Biology in the lab of his mentor Prof. Thomas Rando at Stanford University School of Medicine. He then directed at Stanford/VA Hospital Palo Alto a research team focused on translational medical research in the fields of aging and regenerative medicine.
He is backed by over 20 years of research with a track record of scientific publications in top tier journals and international patents. He also co-founded the biotech company WetWare Concepts and the rejuvenation company Turn Biotechnologies, based on his work conducted at Stanford University with colleague Dr. Sebastiano on transient epigenetic reprogramming. He also sits on the advisory board of the California Institute for Regenerative Medicine (CIRM) – Calpoly program in regenerative medicine. He is in the advisory and research board at the Center for Healthcare Innovation (CHI) and a member of the Paul F Glenn Center for the Biology of Aging Studies at Stanford University.